DECONTRACTANT MUSCULAIRE FORT
Food supplement declared in France, declaration No 2022-12-905
DECONTRACTANT MUSCULAIRE FORT (GRANIONS) is a food supplement declared in France. Status: earlier declaration, replaced by the 2025 declaration. Main ingredients: Cinchona pubescens 260 mg per day, Matricaria chamomilla 150 mg per day, Vitis vinifera 80 mg per day, Biotin (vitamin B8), Calcium. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- GRANIONS
- Food business operator placing the product on the market
- EQUILIBRE ATTITUDE
- Status
- Earlier declaration, replaced by the 2025 declaration : DECONTRACTANT MUSCULAIRE FORT
- Form
- Tablet
- Daily dose
- 4 comprimés /jour
- Directions for use
- Voie orale : 4 comprimés le matin ou 2 comprimés le matin et 2 comprimés le soir avec un verre d’eau
- Not recommended (according to the manufacturer)
- Children (under 12)
- Objectives stated by the manufacturer (these are not authorised claims)
- Antioxidant, Sport
Declaration 303412, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Cinchona pubescens Vahl | Ecorce | Extrait sec aqueux | 260 mg |
| Matricaria chamomilla L. | Fleur | Extrait sec hydroalcoolique | 150 mg |
| Vitis vinifera L. | Feuille | Extrait sec aqueux | 80 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Ubiquinone | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-biotin | Biotin (vitamin B8) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| calcium carbonate | Calcium | 2,500 mg | 800 mg |
| cupric sulphate | Copper | 5,000 µg | 2,000 µg |
| magnesium oxide | Magnesium | 250 mg | 300 mg |
| magnesium bisglycinate | Magnesium | 250 mg | 300 mg |
| nicotinamide | Nicotinamide (vitamin B3) | 900 mg | 54 mg |
| potassium chloride | Potassium | no limit (insufficient data) | 80 mg |
| selenium enriched yeast | Selenium | 255 µg | 50 µg |
| thiamin hydrochloride | Vitamin B1 (thiamine) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| cyanocobalamin | Vitamin B12 | no adverse effect defined | dose annulled by the French Council of State in 2011 |
| riboflavin | Vitamin B2 (riboflavin) | no limit (insufficient data) | dose annulled by the French Council of State in 2011 |
| pyridoxine hydrochloride | Vitamin B6 | 12 mg | 2 mg |
| cholecalciferol | Vitamin D | 100 µg (4,000 IU) | 5 µg (200 IU) |
| DL-alpha-tocopheryl acetate | Vitamin E | 300 mg | 30 mg |
Additives
E504, E460, E1202, E1450, E471, E414, E341, E307, E330, E331
Other ingredients
amidon de maïs, maltodextrine, huile végétale
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Label warnings
Le complément alimentaire ne doit pas se substituer à une alimentation variée et équilibrée et à un mode de vie sain. Ne pas dépasser la dose recommandée. À tenir hors de la portée des jeunes enfants. De manière générale, il est recommandé d’inviter les femmes enceintes et allaitantes à prendre l’attache d’un professionnel de santé avant toute complémentation.L'emploi est déconseillé chez les enfants de moins de 12 ans (Quinquina).
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Matricaria chamomilla L.
Read the warning, when it applies and the studies cited
GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000; WHO 1999; Bradley 1992).
Cautions and warnings
When using this product exercise caution if you drive or use machinery as you may experience drowsiness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. 2003. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
Health Canada monograph dated 19 December 2025
German Chamomile - Matricaria Chamomilla Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Health Canada monograph dated 31 January 2025
GERMAN CHAMOMILE - MATRICARIA CHAMOMILLA Buccal
Route of administration: Buccal (ESCOP 2003; Blumenthal et al. 2000; Bradley 1992)
Cautions and warnings
Ask a healthcare practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (ESCOP 2003; Bradley 1992).
Sources cited by Health Canada (2)
- Bradley PR, editor. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association; 1992.
- ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Ubiquinone
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- DECONTRACTANT MUSCULAIRE FORT GRANIONS, declared in 2025 : different composition: 3 ingredient(s) added, 11 missing
- DECONTRACTANT MUSCULAIRE FORT GRANIONS, declared in 2023 : different composition: 3 ingredient(s) added, 12 missing
Brand : GRANIONS
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.